Capricor Therapeutics, Inc. · NASDAQ:CAPR
Capricor Therapeutics — Q4 2020 Earnings Presentation
18 slides from Capricor Therapeutics's earnings presentation, Mar 11, 2021
Slide 1: Fourth Quarter Earnings Call Exosome-mRNA Platform Data Presentation
Fourth Quarter Earnings Call Exosome-mRNA Platform Data Presentation March 11, 2021 NASDAQ: CAPR 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding
Slide 3: Call Participants
Call Participants Stephen J. Gould, Ph.D. – Professor of Biological Chemistry at Johns Hopkins University and Executive Consultant to Capricor Linda Marban, Ph.D. – Capricor Chief Executive Officer AJ Bergmann – Capricor Chief Financial Officer Capricor Therapeutics, Inc. Developing Transformative T
Slide 4: RNA Therapeutics are a New Class of Medicines
RNA Therapeutics are a New Class of Medicines Broad Market Opportunities Capital Efficiency for Development Rapid Innovation Possible Proof of Concept Established in Vaccines Barrier to Success: Systems of Nucleic Effective Delivery Acids Capricor Therapeutics, Inc. Developing Transformative Therapi
Slide 5: Exosomes are a Natural Drug Delivery System
Exosomes are a Natural Drug Delivery System • • • • ~100 nanometer vesicles Made by nearly all cells Abundant in blood and all biofluids Transfers signals and molecules to other cells Decades of transfusion and transplantation medicine demonstrates safety Can be used to deliver RNAs and other drugs
Slide 6: Exosomes Platform Goals: Building a New Class of Therapeutics
Exosomes Platform Goals: Building a New Class of Therapeutics Monogenic Diseases RNA therapeutics Oncology Vaccines & targeted delivery therapeutics Inflammatory & Vascular Biologics Infectious Diseases Vaccines Nucleic Acids EXOSOMES CELL Scale Goals platform and IP through Capricor Therapeutics, I
Slide 7: Exosome Platform: Potential Vaccines and Therapeutics
Exosome Platform: Potential Vaccines and Therapeutics Therapeutics: Modalities Exosomes: Platform for RNA & Drug Delivery Tar Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 7 01 Vaccines 02 Therapeutics RNA Delivery 03 Therapeutics: Biologics 04 Small Molecule
Slide 8: Exosomes: Less Toxic than Lipid Nanoparticles
Exosomes: Less Toxic than Lipid Nanoparticles • 30 * Day Day 0 3 • • I I • - 28 E -.C.) C'CS s... 26 .!: C) (1) • 24 • Control Exos LNPs I Developing Transformative Therapies from Bench to Bedside 8 Capricor Therapeutics, Inc. Results from bioRxiv, Gould 2021
Slide 9: Exosomes: Less Toxic than Lipid Nanoparticles
Exosomes: Less Toxic than Lipid Nanoparticles -"-0 s::::: 0 (J tJl 0 , >< CJ) atn.. z ...J atn.. z ...J I Developing Transformative Therapies from Bench to Bedside 9 Capricor Therapeutics, Inc. Results from bioRxiv, Gould 2021
Slide 10: Exosomes: More Efficient mRNA Delivery
Exosomes: More Efficient mRNA Delivery Control Exo-mRNA Antares2 Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 10 Results from bioRxiv, Gould 2021
Slide 11: Capricor's Exosome-mRNA Delivery Platform: A real-time view of mRNA delivery
Capricor’s Exosome-mRNA Delivery Platform: A real-time view of mRNA delivery, protein expression and enzymatic activity Control Exo-mRNA Antares2 Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 11 Results from bioRxiv, Gould 2021
Slide 12: Exosome Platform: Potential Vaccines and Therapeutics
Exosome Platform: Potential Vaccines and Therapeutics Therapeutics: Small Molecule utics livery Therapeutics: Biologics Modalities Exosomes: Platform for RNA & Drug Delivery Vascular Disorders ses & Tar Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 12 01 Vacci
Slide 13: Exosome-mRNA Preclinical Vaccine Data
Exosome-mRNA Preclinical Vaccine Data Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 13 •Safe, non-toxic exosome-mRNA formulation •Drives cell and antibody immunity to nucleocapsid protein (SARS-CoV-2) •Drives cell and antibody immunity to spike protein (SARS-C
Slide 14: Exosome-mRNA Preclinical Vaccine Data
Exosome-mRNA Preclinical Vaccine Data A A N-induced proliferation LSNMEISW1 injection day1 l LSNMEISW1 injection day21 l LSNMEISW1 injection day42 l e Untreated • Exo-mRNA (0.25 microgram) .... c:: A Exo-mRNA (4 microgram) E t blood day35 t blood day 56 t blood day70 t blood &organs day84 t blood da
Slide 15: Exosome Platform: Potential Vaccines and Therapeutics
Exosome Platform: Potential Vaccines and Therapeutics Therapeutics: utics: Modalities Exosomes: Platform for RNA & Drug Delivery mmatory, Evaluating Tar Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 15 01 Vaccines 02 Therapeutics RNA Delivery 03 Therape Biolog
Slide 16: Capricor's Exosome-mRNA Delivery Platform: A real-time view of mRNA delivery
Capricor’s Exosome-mRNA Delivery Platform: A real-time view of mRNA delivery, protein expression and enzymatic activity Control Exo-mRNA Antares2 Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 16 Results from bioRxiv, Gould 2021
Slide 17: Capricor Corporate Summary
Capricor Corporate Summary • • Cell and exosome-based platform therapeutics company Products with novel approaches to neuromuscular, infectious, inflammatory and cardiovascular diseases Expanding engineered exosome platform delivering RNA Late-stage clinical development in DMD and rapidly progressin
Slide 18: Thank you Questions and Answers
Thank you Questions and Answers Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 18
Capricor Therapeutics — Q4 2020 Earnings Presentation on 6ix